drugset / Trial / NCT00865111

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

NCT00865111

Phase 1 Completed 26 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg sustained release tablet to that of Wellbutrin SR sustained release tablet after a single, one-tablet dose in fasted subjects.

Timeline

Start
2006-03
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg

Indications

No indication recorded.